Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

Bladder Cancer Clinical Trial

Official title:

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06337305
• Other study ID #: STUDY00146138
• Status: Completed
• Start date: August 19, 2020
• Est. completion date: August 19, 2023

Study information

• Verified date: March 2024
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies.

Description:

This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies. Primarily, the study will evaluate health related quality of life and resiliency in patients throughout the perioperative course of a radical cystectomy for bladder cancer.

The primary objective will be the correlation of the Connor-Davidson Resilience Scale (CD-RISC-25) and the Functional Assessment of Cancer Therapy-Bladder-Cystecomy (FACT-BL-Cys) score.

Patients will be identified and undergo consent and baseline assessments, including completion of surveys prior to their cystectomy. A retrospective chart review will also be completed to record information regarding patient's cancer stage, treatment status, diagnosis date, insurance type, and related medical conditions and medications. Data from retrospective chart review will be collected and recorded in a secure REDCap database for all eligible patients.

Subsequent surveys will be administered again at approximately 10-30 days postoperatively, as well as 60-120 days postoperatively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: August 19, 2023
• Est. primary completion date: August 19, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of bladder cancer

• Patients electing to undergo radical cystectomy as treatment

• = 18 years of age

• Able to speak and read English

• Willing and able to provide informed consent

• Functioning telephone number or access to one

Exclusion Criteria:

• Patients opting to not undergo radical cystectomy

• Minors

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Locations

Country	Name	City	State
United States	University of Kansas Medical Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in resiliency as measured by the Connor-Davidson Resilience Scale (CD-RISC-25).	The Connor-Davidson Resilience scale is a 25-item self-administered instrument for assessing resilience that is consistent in a variety of populations, including clinical and community.; Scoring: 0-100 (sum total of all items, each of which is scored 0-4). Higher score reflects greater resilience.	Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operative
Primary	Change in quality of life in patients undergoing radical cystectomy as measured by the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-Bl-Cys).	The FACT-BL-Cys is a condition-specific instrument for patients undergoing radical cystectomy to measure quality of life.; Scoring: 0-168 (sum total of all items). Higher score reflects better health-related quality of life.	Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operative
Primary	Change in quality of life in patients undergoing radical cystectomy as measured by the PROMIS-29.	The PROMIS-29 is a disease non-specific measure of pain intensity using a 1-5 rating and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance).; Scoring: High scores mean more of the concept being measured.	Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operative
Secondary	Identification of clinical and demographic factors in bladder cancer patients	Identify clinical and demographic factors related to higher post-cystectomy resiliency in patients with bladder cancer.	Baseline to 90-days (+/-30 days) post-operative
Secondary	Demographics	Characterize trends that correspond with greater levels of resiliency and quality of life	Baseline to 90-days (+/-30 days) post-operative